Letter: Tonsillectomy bleeding.

F. Catlin

A M A Archives of Otolaryngology

Abstract:

What problem does this paper attempt to address?

P934 A delphi consensus on the optimisation of medical and surgical therapy in perianal fistulising Crohn’s disease, targeted at individual TOpCLASS classification groups

L Hanna,S Anandabaskaran,N Iqbal,J Geldof,J F LeBlanc,A Dige,L Lundby,G Bislenghi,B Verstockt,A D'Hoore,S Vermeire,D De Looze,T Lobaton,D Van de Putte,I De Kock,M Carvello,A Spinelli,S Danese,C J Buskens,K Gecse,R Hompes,J D W van der Bilt,W A Bemelman,S Sebastian,G W Moran,A Lightner,S Y Wong,B L Cohen,S Holubar,N S Ding,C Behrenbruch,K Sahnan,R Misra,P Lung,A Hart,P Tozer

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1064

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Perianal fistulising Crohn’s Disease (PFCD) is a challenging phenotype of IBD associated with poor outcomes. Classically, fistulae have been classified anatomically and guidelines have been generalised, with a lack of appreciation of disease heterogenicity. The recent ‘TOpCLASS classification system’ (Geldof et al. (2022) - figure below) addresses this and categorises patients based on clinical features and patient goals. There is a need to provide management guidance for PFCD that aligns with this approach, targeting differing PFCD manifestations seen in real-life. We present a consensus exercise delivering that guidance. Methods Position statements on ‘optimal’ PFCD management within the TOpCLASS classes were made via a consensus meeting in Apr 2023. The expert panel were members of the TOpCLASS Consortium, a group of PFCD specialists and researchers. This included 15 surgeons and 16 gastroenterologists, from IBD centres in Europe, North America, and Australia. Prior to the meeting, to inform provisional statements: 1) a systematic review of the literature was conducted (Oct 2021), 2) multidisciplinary team responses on the management of fictional PFCD cases from 8 leading IBD centres were obtained, and 3) an open discussion on PFCD management with the expert panel was conducted. Consensus was predefined as ≥80% ‘strongly agree’ [A+] or ‘agree with minor reservation’ [A]. Results 53 position statements were agreed by the expert panel. For Class 1 (minimal, asymptomatic) disease the panel agreed, given the lack of symptoms, there is no role for seton insertion (A+ 50%, A 50%), and no role for routine MRI monitoring in the absence of new fistula symptoms (A+ 46%, A 54%). Regarding Class 2 (chronic, symptomatic) disease, the panel agreed on detailed guidance for when fistulae are suitable for a repair attempt and where differing surgical modalities are best utilised in fistula repair. Additionally, statements on seton removal in PFCD were made, alongside statements on optimised medical therapy in Class 2 patients. Specifically, the panel suggest Infliximab first-line (A+ 80%, A 20%), ideally commenced within 30 days of initial drainage +/- seton insertion (A+ 100%). Statements were also produced regarding second-line options, topical therapy, and loss of response to biologics in PFCD. Specific statements were also developed for Class 2b, 2c-i, 2c-ii, and 4 disease, as well as on the psychological burden of PFCD. Conclusion The generated statements come from a highly expert Western group of PFCD specialists. We believe they provide pragmatic advice to gastroenterologists and IBD surgeons managing the full breadth of PFCD encountered in day-to-day practice.

gastroenterology & hepatology
TOpCLASS Expert Consensus Classification of Perianal Fistulizing Crohn’s Disease: A Real-World Application in a Serial Fistula MRI Cohort

Matthew K Schroeder,Suha Abushamma,Alvin T George,Balakrishna Ravella,John Hickman,Anusha Elumalai,Paul Wise,Maria Zulfiqar,Daniel R Ludwig,Anup Shetty,Satish E Viswanath,Chongliang Luo,Shaji Sebastian,David H Ballard,Parakkal Deepak

DOI: https://doi.org/10.1093/ecco-jcc/jjae056

2024-04-20

Journal of Crohn's and Colitis

Abstract:Abstract Background and Aims Perianal fistulizing Crohn’s disease (PFCD) is an aggressive phenotype of Crohn’s disease defined by frequent relapses and disabling symptoms. A novel consensus classification system was recently outlined by the TOpCLASS consortium that seeks to unify disease severity with patient-centered goals but has not yet been validated. We aimed to apply this to a real-world cohort and identify factors that predict transition between classes over time. Methods We identified all patients with PFCD and at least one baseline and one follow-up pelvic (pMRI). TOpCLASS classification, disease characteristics, and imaging indices were collected retrospectively at time periods corresponding with respective MRIs. Results We identified 100 patients with PFCD of which 96 were assigned TOpCLASS Classes 1 – 2c at baseline. Most patients (78.1%) started in Class 2b, but changes in classification were observed in 52.1% of all patients. Male sex (72.0%, 46.6%, 40.0%, p = 0.03) and prior perianal surgery (52.0% vs 44.6% vs 40.0%, p = 0.02) were more frequently observed in those with improved class. Baseline pMRI indices were not associated with changes in classification, however, greater improvements in mVAI, MODIFI-CD, and PEMPAC were seen among those who improved. Linear mixed effect modeling identified only male sex (-0.31, 95% CI -0.60 to -0.02) with improvement in class. Conclusion The TOpCLASS classification highlights the dynamic nature of PFCD over time, however, our ability to predict transitions between classes remains limited and requires prospective assessment. Improvement in MRI index scores over time was associated with a transition to lower TOpCLASS classification.

gastroenterology & hepatology
Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus

Serre-Yu Wong,Cathy Rowan,Elvira Diaz Brockmans,Cindy C Y Law,Elisabeth Giselbrecht,Celina Ang,Sergey Khaitov,David Sachar,Alexandros D Polydorides,Leon Shin-Han Winata,Bram Verstockt,Antonino Spinelli,David T Rubin,Parakkal Deepak,Dermot P B McGovern,Benjamin D McDonald,Phillip Lung,Lilli Lundby,Amy L Lightner,Stefan D Holubar,Luke Hanna,Carla Hamarth,Jeroen Geldof,Anders Dige,Benjamin L Cohen,Michele Carvello,Cristiana Bonifacio,Gabriele Bislenghi,Corina Behrenbruch,David H Ballard,Emre Altinmakas,Shaji Sebastian,Phil Tozer,Ailsa Hart,Jean-Frederic Colombel

DOI: https://doi.org/10.1016/j.cgh.2024.05.029

2024-06-12

Abstract:Background & aims: Perianal fistulizing Crohn's disease (PFCD)-associated anorectal and fistula cancers are rare but often devastating diagnoses. However, given the low incidence and consequent lack of data and clinical trials in the field, there is little to no guidance on screening and management of these cancers. To inform clinical practice, we developed consensus guidelines on PFCD-associated anorectal and fistula cancers by multidisciplinary experts from the international TOpClass consortium. Methods: We conducted a systematic review by standard methodology, using the Newcastle-Ottawa Scale quality assessment tool. We subsequently developed consensus statements using a Delphi consensus approach. Results: Of 561 articles identified, 110 were eligible, and 76 articles were included. The overall quality of evidence was low. The TOpClass consortium reached consensus on 6 structured statements addressing screening, risk assessment, and management of PFCD-associated anorectal and fistula cancers. Patients with long-standing (>10 years) PFCD should be considered at small but increased risk of developing perianal cancer, including squamous cell carcinoma of the anus and anorectal carcinoma. Risk factors for squamous cell carcinoma of the anus, notably human papilloma virus, should be considered. New, refractory, or progressive perianal symptoms should prompt evaluation for fistula cancer. There was no consensus on timing or frequency of screening in patients with asymptomatic perianal fistula. Multiple modalities may be required for diagnosis, including an examination under anesthesia with biopsy. Multidisciplinary team efforts were deemed central to the management of fistula cancers. Conclusions: Inflammatory bowel disease clinicians should be aware of the risk of PFCD-associated anorectal and fistula cancers in all patients with PFCD. The TOpClass consortium consensus statements outlined herein offer guidance in managing this challenging scenario.
DOP04 Screening and management of fistula cancers in patients with perianal fistulising Crohn’s Disease: an expert consensus

S Y Wong,C Rowan,C C Law,E D Brockmans,S Khaitov,D Sachar,E Altinmakas,D Ballard,C Behrenbruch,G Bislenghi,C Bonifacio,M Carvello,B Cohen,P Deepak,A Dige,J Geldof,L Hanna,C Harmath,S Holubar,L Lundby,A Lightner,P Lung,B McDonald,D McGovern,D Rubin,S Sebastian,A Spinelli,B Verstockt,L S H Winata,P Tozer,A Hart,J F Colombel

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0044

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Fistula cancer is a rare and often devastating diagnosis in patients with perianal fistulising Crohn’s disease (CD). Fistula cancer management is a complex process requiring multi-disciplinary effort. However, given the low incidence and subsequent lack of data and clinical trials in the field, there is little to no guidance on screening and management of fistula cancer. To inform clinical practice, we developed consensus guidelines on fistula cancer in perianal fistulising Crohn’s disease by multidisciplinary experts from the international TOpCLASS consortium. Methods We performed a systematic review of the literature by standard methodology, using the Newcastle-Ottawa quality assessment tool. Data were retrieved from articles according to these domains: epidemiology and risk factors, clinical presentation, diagnostics, staging, and treatment. We developed consensus statements using a Delphi consensus approach. Participants included gastroenterologists, surgeons, radiologists, and pathologists. We performed two rounds of voting: (1) online survey followed by statement edits and (2) hybrid meeting with discussion until over 80% consensus was achieved for each statement. Results Of 550 articles identified, 99 were eligible, and 80 articles were included. The overall quality of evidence was low. Seven statements were accepted in the final consensus (Table 1). Patients with longstanding (>10 years) perianal fistulising CD should be considered at small but increased risk of developing fistula cancer, including anal squamous cell cancer (SCC) and anorectal carcinoma. Risk factors for anal SCC, including human papilloma virus (HPV), should be considered. Clinical signs and symptoms of fistula cancers are non-specific, and several case reports included asymptomatic patients. New or refractory/progressive perianal symptoms should prompt evaluation for fistula cancer. There was no consensus on timing or frequency of screening in patients with asymptomatic perianal fistula. Regarding diagnostics, multiple modalities may be required, including repeated exam under anesthesia with biopsy. Multidisciplinary team efforts were deemed central for the management of fistula cancers. Conclusion Clinicians managing patients with perianal fistulising CD should be aware of the risk of fistula cancers, including anal SCC and anorectal carcinoma. Our expert consensus recommends consideration of patient factors including duration of fistulas, HPV status, and perianal symptoms, and gives guidance on diagnostic modalities and treatment considerations. Multidisciplinary coordination of care is paramount, and more studies in the field are needed.

gastroenterology & hepatology
P498 An expert Delphi consensus: Early identification of patients at risk of Crohn's disease in perianal fistulas and abscesses (PREFAB) and identification and management of isolated perianal Crohn's disease (ipCD) - Part B, ipCD

L Hanna,L Munster,A Dige,L Lundby,C J Buskens,A L Hart,J D W van der Bilt,P J Tozer,The TOpCLASS perianal Crohn's disease Consortium . The Dutch Initiative on Crohn and Colitis and the Initiative on Crohn and Colitis Surgery . This abstract is a partner to the PREFAB abstract with the same authorship,

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0628

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background In clinical practice, some patients with ‘idiopathic’ perianal fistulae (iPAF) and no evidence of luminal IBD are labelled ‘isolated perianal Crohn’s disease’ (ipCD) and treated with IBD-directed therapies. However, there are no accepted criteria to guide which patients should be diagnosed as ipCD, or how they should be managed. This project aimed to provide a definition of ipCD, strategies for management, and a platform for building further understanding of this group. Methods An expert panel of IBD gastroenterologists, surgeons and radiologists took part in a Delphi consensus on ipCD. The first-round was an electronic survey, probing: 1) personal experience of ipCD; 2) how fistula histology may influence ipCD diagnosis; 3) patient and fistula features suggestive of ipCD; and 4) suggested management of patients with suspected-ipCD. Responses informed the creation of clinical criteria for ipCD, and statements on ipCD management, which were discussed, amended, and agreed-upon at a second-round virtual consensus meeting. Consensus was predefined as ≥70% ‘strongly agree’ or ‘agree with minor reservation’. Results >30 specialists participated. In round 1: 93% agreed ipCD is a separate Crohn’s phenotype; 83% reported having treated ipCD patients with IBD medical therapies; 73% agreed iPAF patients with fistula histology suggestive of ipCD could be labelled as histologically-confirmed ipCD; and 93% agreed histologically-confirmed ipCD with complex fistulation should be treated with IBD medical therapy (e.g., biologics). However, there was no consensus on the appropriateness of IBD medical therapy for simple fistulae. For iPAF patients without histological evidence of IBD, the panel agreed factors suggestive of ipCD. These included: family history of IBD, symptoms of IBD extraintestinal manifestations, co-existent/previous perianal lesions (fissures, anal stricture, tags), and certain fistula features. Factors were used to produce a criteria to diagnose ipCD and identify patients appropriate for a trial of medical therapy. If a trial of therapy is pursued, the panel agreed careful discussion of the risks of treatment, and known-unknowns, when treating ipCD. Optimised anti-TNF is preferred first-line (82% agreement) with a careful review of treatment response, and contemporaneous MRI, at 6-12 months (93% agree). Conclusion ipCD is a contentious label and standardisation of the diagnosis could help us better assess this group and their treatment outcomes. We present a suggested criteria for diagnosing this group, and a pragmatic approach to trialling biologic therapy. Key to managing this group is honest discussion regarding the known-unknowns of ipCD treatment, to manage patient expectations and support a joint decision-making approach.

gastroenterology & hepatology
Soft tissue inflammations-bursitis-tendinitis-synovitis.

D. Ford

1968-04-01

Abstract:PAINFUL SHOULDERS The shoulder joint seems to be particularly susceptible to attacks of pain and limitation of motion and the reason for this may lie in the extraordinary mobility of the joint. Pain in the shoulder is often referred pain from cervical nerve root irritation and this can usually be established fairly readily from the observations that the pain is aggravated by motion of the neck, is related to particular postures of the neck, is worse at night and is not associated with a limited range of motion. Shoulder problems are only rarely due to actual arthritis of the gleno-humeral joint and, excluding referred pain, the great majority of painful shoulder syndromes with stiffness are caused by abnormalities in the bursae or periarticular tendinous cuff around the joint. There has always been much confusion about the painful stiff shoulder syndrome and a profuse terminology only adds to the confusion. Such terms as periarthritis, capsulitis, tendinitis, subacromial bursitis and rotator-cuff tears are often applied to Ri-defined situations and the nomenclature of orthopedic surgeons may differ from that of rheumatologists. Sometimes, but not always, this results from the natural tendency of traumatic lesions to be seen by orthopedists while "spontaneous" syndromes migrate to rheumatologists. The following comments are based on the viewpoint of a rheumatologist.
Perianal fistulizing Crohn's disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies

Jalpa Devi,David H Ballard,Tina Aswani-Omprakash,Alyssa M Parian,Parakkal Deepak

DOI: https://doi.org/10.1007/s12664-024-01524-2

Abstract:Crohn's disease (CD), a chronic inflammatory bowel disorder, manifests in various phenotypes, with fistulizing perianal CD (CD-PAF) being one of its most severe phenotypes. Characterized by fistula formation and abscesses, CD-PAF impacts 17% to 34% of all CD cases and with a significantly deleterious impact on patient's quality of life, while increasing the risk for anorectal cancers. The pathogenesis involves a complex interplay of genetic, immunological and environmental factors, with cytokines such as tumor necrosis factor-alpha (TNF-α) and transforming growth factor-beta (TGF-β) playing pivotal roles. Diagnostic protocols require a multi-disciplinary approach including colonoscopy, examination under anesthesia and magnetic resonance imaging. In terms of treatment, biologics alone often prove inadequate, making surgical interventions such as setons and fistula surgeries essential. Emerging therapies such as mesenchymal stem cells are under study. The South Asian context adds layers of complexity, including diagnostic ambiguities related to high tuberculosis prevalence, healthcare access limitations and cultural stigma toward perianal Crohn's disease and ostomy surgery. Effective management necessitates an integrated, multi-disciplinary approach, especially in resource-constrained settings. Despite advances, there remain significant gaps in understanding the disease's pathophysiology and a dearth of standardized outcome measures, underscoring the urgent need for comprehensive research.
P946 Real life management of patients with active perianal fistulizing Crohn’s disease (ALERT-CD study)

M Bak,L Stassen,C Buskens,A Pronk,J van der Bilt,K Gecse,N de Boer,C Witjes,C Fitzpatrick,L Nissen,E Verdaasdonk,M Pierik,S Breukink,L Gillissen,J Bloemen,R West,R Kortekaas,W Mares,G de Jong,S Jansen,B Bloemendaal,M Sikkema,D Zimmerman,K Peeters,A van der Meulen- de Jong,F van Schaik,M Richir,K van Dongen,M Duijvestein,F Hoogenboom,M Visschedijk,A de Vries,O van Ruler

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1076

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background The multitude of medical and surgical treatment options for perianal fistulizing Crohn’s disease (pCD) impels differences in management. This study aimed to assess management of pCD in current clinical practice in the Netherlands. Methods Patients with active pCD (i.e. visible external fistula opening or patent fistula tract on imaging) were included in a prospective multicenter cohort study in 41 Dutch academic and non-academic hospitals from September 2022 to March 2023. pCD-related clinical, radiological and surgical data were prospectively collected during a follow-up period of 6 months and retrospectively collected from pCD diagnosis until inclusion. Primary outcome of the study was adherence to the international guidelines on pCD management during the disease course (from pCD diagnosis until end of follow-up). Adequate adherence was defined as (I) imaging for pCD diagnosis using magnetic resonance imaging (MRI) and/or endo-anal ultrasound (EUS), (II) endoscopic evaluation of concomitant proctitis, (III) use of antibiotics for symptomatic response, (IV) initiation of an anti-tumour necrosis factor (TNF) agent for maintenance therapy, (V) fistula surgery aiming at fistula closure in case of surgically amendable disease and (VI) decision making by a multidisciplinary team (gastroenterologist and surgeon)(Figure 1). Results 449 patients with active pCD (52% female) were included(Table 1). At inclusion, median age and median pCD duration were 37.2 years (IQR 28.8–49.4) and 3.1 years (IQR 1.1–7.1). 54% of patients were treated in a non-academic hospital. 89% of patients were treated with CD medication, which concerned anti-TNF agents in 82% of these patients. As recommended by guidelines, a MRI (99%) and/or EUS (9%) were performed in the vast majority of patients (97%) for pCD diagnosis. Following diagnosis, endoscopy was performed in 81% of patients. During the disease course, antibiotics were initiated in 55% of patients and at least one anti-TNF agent(s) was started in 84% of patients for maintenance therapy (73% infliximab, 53% adalimumab, 26% both agents). Surgery aiming for fistula closure was performed in 38% of patients during the disease course. 60% of patients were discussed in a multidisciplinary team (MDT). Conclusion This study demonstrated a high adherence to international guidelines on pCD management concerning imaging at diagnosis, endoscopic evaluation for concomitant proctitis and treatment with anti-TNF agents. Adherence to use of antibiotics for symptoms, performance of fistula surgery aiming at fistula closure and decision making in a MDT is moderate and standardization may optimize pCD management.

gastroenterology & hepatology
P736 Class 4 Fistulizing Perineal Disease after Proctectomy for Crohn’s Disease: A Multicentre Study

A Khan,I Khan,T Ward,B Cohen,M Valente,S Holubar

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0866

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background The TOpCLASS International Consortium recently described a paradigm shifting classification scheme for perianal Crohn’s disease, based on the desired patient goals of care. Class 4 perineal fistulizing disease is a CD that persists after proctectomy, and there are limited data defining this entity. We sought to determine the rates of clinical perineal fistulizing disease after proctectomy and to secondarily define the risk factors for recurrence. Methods Adult patients with CD who underwent perineal resection with proctectomy or proctocolectomy at three hospitals within our institution’s health network between 2009 and 2021 were retrospectively reviewed. The exclusion criteria included a preoperative diagnosis of ulcerative colitis or indeterminate colitis, and patients who underwent restorative proctectomy. Extracted data included baseline demographic data, preoperative medical treatment for CD, proctectomy indication, clinical recurrence of perineal disease, and resolution of perineal disease. Results A total of 405 patients with Crohn’s disease were included, including 190 (46.9%) who underwent proctectomy and 215 (53.1%) who underwent proctocolectomy. The median age was 44 years (IQR 33-58) and 58.8% of the patients were female. Within three months prior to surgery, 36% were exposed to biologic therapy, 29.1% to immunomodulators, and 11.4% to corticosteroids. During a median follow-up of 4 years, clinical recurrence of fistulizing perineal CD occurred in 62 (15.3%) patients, including five patients with perineal-vaginal fistulas and one with adenocarcinoma in the fistula tract. The median time to the development of perineal disease was 6.5 months (IQR 3-23 months). Factors associated with perineal disease included younger age (38 vs. 46 years; p <0.01), female sex (71% female vs. 56.6% female; p=0.03), preoperative corticosteroid use (19.4% vs. 9.9%; p=0.031), and the presence of perianal CD, regardless of the indication for proctectomy (85.4% vs 60.1%; p<0.01). After treatment for class 4 disease, perineal symptom resolution was observed in 40 (62.9%) patients. There were 79 (19.5%) patients underwent examination under anesthesia (EUA) for perineal disease, with a median of 2 EUA’s (range 1-21). Preoperative biological therapy was not associated with recurrent perineal disease (p= 0.29). Conclusion Perineal CD after proctectomy is common and frequently requires multiple surgical interventions. Younger age, female sex, preoperative corticosteroid use, and the presence of perianal disease may benefit from a more intensive postoperative review and consideration of the continuation or early initiation of prophylactic post-proctectomy CD medical management with biologics.

gastroenterology & hepatology
P199 Analysis of Clinical Features of Asymptomatic Perianal Fistulizing Crohn’s Disease

T. Wu,L. Huang,Q. Cao

DOI: https://doi.org/10.1093/ecco-jcc/jjab076.325

2021-01-01

Journal of Crohn s and Colitis

Abstract:Abstract Background Perianal fistula represents an aggressive phenotype of Crohn’s disease (CD), and is detected in CD patients without perianal complains. Data of CD patients with asymptomatic perianal fistula is scarce. Our study targets to assess the clinical characteristics of adult CD patients with asymptomatic perianal fistulas in adults with CD. Methods This retrospectively study collected data from Sir Run Run Shaw Hospital. Newly diagnosed CD patients undergoing magnetic resonance imaging examinations during 2014–2019 were enrolled. The perianal fistulizing CD patients were divided into two groups: 1) symptomatic perianal fistula group, 2) asymptomatic perianal fistula group, then we analyze the features of clinical features, medication and prognosis of each group. Results Among 437 CD patients, 346 (79.2%) had perianal fistulas whereas 91 (20.8%) did not. In patients with perianal fistulas, 89 (25.7%) did not have perianal symptoms. Comparing to symptomatic perianal fistula group, asymptomatic perianal fistula group combined with lower perianal abscess incidence (73.9% vs. 25.8%, p < 0.001). According to Park’s classification, the most common type of fistula in these two groups was intersphincteric fistula (73.2% vs. 53.2% p=0.094). Patients with asymptomatic perianal fistulas were described by the following features when compared with patients with symptomatic perianal fistulas: higher rate of female sex (38.2% vs. 17.9%, p < 0.001), shorter disease duration at enrolment (0.8 vs. 1.0 years, p = 0.001), higher rate of stricturing behavior (32.6% vs. 18.7%, p < 0.01), worse outcomes of laboratory examinations at diagnosis, including hemoglobin (119.0 vs. 131.0 g/dL, p < 0.001), platelet (333.0 vs. 283.0 *10^9, p < 0.001), ESR (20.0 vs. 14.0 mm/H, p < 0.01), albumin (35.6 vs. 37.5 g/L, p = 0.001), C-reactive protein (27.3 vs. 15.7 mg/L, p = 0.001). The age at diagnosis and disease locations were not different. For asymptomatic perianal fistula patients, antibiotics (57.3%) and surgery (6.7%) were taken at diagnosis. The usage of biologics at diagnosis showed no difference (59.6% vs. 40.4% p=0.108). Regarding clinical outcomes, the cumulative probabilities for bowel surgery (p < 0.05) and bowel obstruction (p < 0.01) in asymptomatic perianal fistula group were higher than symptomatic perianal fistula group. Conclusion Asymptomatic perianal fistulas account for a certain proportion. Female sex, shorter disease duration, stricturing behavior and poor outcomes of laboratory examinations at diagnosis are associated with detection of asymptomatic perianal fistulas. We should pay more attention to CD patients with asymptomatic perianal fistulas because they may have poor prognosis or even worse as patients with symptomatic perianal fistulas.
P1129 Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program

J Mcnamara,W Wilson,J L Pipicella,S Ghaly,R Gearry,J Begun,W Ng,K Lynch,I Lawrance,M Schultz,G Walker,G Radford-Smith,J M Andrews,S J Connor

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.1259

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Fistulising Crohn’s disease (fCD) affects up to 40% of people with Crohn’s disease (CD) over their lifetime, leading to perianal pain, faecal incontinence and sepsis. Despite its high prevalence, the burden of disease, treatment and “natural history” in the current biologic therapy era are poorly described. This study explored demographics, disease and treatment factors in a real-world cohort Methods The clinical quality registry (CQR) is created from deidentified data flowing into a registry during documentation in routine care. The CQR was interrogated in December 2022. People with CD with a care encounter in the last 14 months at one of 20 treating centres were included (n=3039). People with a current fistula were defined as those with an actively draining fistula on most recent clinical assessment, radiologic or endoscopic investigation. Previous fCD was defined as the prior presence of a fistula with most recent documentation showing resolution Results There were 3039 people with CD with a mean age of 43.1 years (SD +/- 16.23). 49% of the total CD cohort were female with a mean disease duration of 13.7 years (SD +/- 10.1). 532 (17.5%) people with CD had fCD documented in the CQR, with 220 current and 312 previous fCD. People with current or previous fCD were younger than those with no prior fistulising disease (40.5 & 39.6 vs 44.1, p=0.005 & p<0.001). Male gender was more commonly seen in those with current (58% p=0.022) or previous fCD (58% p=0.007) compared to those with no prior fCD (50% n=1270) People with current and previous fCD had higher rates of current biologic use compared to those with no prior fCD recorded (75.5% & 68.3% vs 48.9%, p<0.001 & p<0.001, respectively). Of those on biologic therapy, people with current or previous fistula were more likely to be on anti-TNF therapy (Adalimumab or Infliximab) compared to those with no history of fCD (85.5% & 82.2% vs 68.1%; p<0.001 & p<0.001 respectively). People with active or previous fCD were less likely to have ever been on steroid therapy compared to those without a history of fistulising disease (23.6%, 24.4% & 32.3%, p<0.001 & p<0.001) People with current or previous fCD had higher rates of CD-related hospital admissions compared to those without a history of fCD (5% & 6% vs 1.9%, p<0.001 and p<0.001 respectively). People with previous fistulising disease had higher rates of surgery within the last 12 months compared to people with no prior fCD (21.2% vs 13.3%, p<0.001) Conclusion People with current and previous fCD continue to experience higher hospitalisation rates for disease related complications and more frequently require surgical procedures. This highlights the importance of proactive management of fCD to reduce morbidity and avoidable healthcare utilisation

gastroenterology & hepatology
P547 Improved clinical and radiologic healing of Crohn’s perianal fistulas using a novel coordinated care model optimising medical and surgical treatments: A prospective real-world observational study

M De Gregorio,L S Winata,I Hartley,C C Behrenbruch,S J Connor,B D‘Souza,C Basnayake,G R Guerra,M J Johnston,M A Kamm,J O Keck,M Lust,O Niewiadomski,E J S Ong,J D Schulberg,A Srinivasan,T Sutherland,R J Woods,E K Wright,W R Connell,A J Thompson,N S Ding

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0677

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Despite best standard care, sustained healing rates of Crohn’s perianal fistulas remain low. A novel coordinated multi-disciplinary care model optimising medical and surgical treatment was established with the aim to improve fistula healing rates. Methods A prospective real-world observational study evaluated the efficacy of this new care model in adults with Crohn’s perianal fistulas. Patients seen through the new care model were sequentially invited to participate, between March 2021 to April 2022, and included irrespective of disease activity, duration, or prior treatments. Three dynamic stages of care were directed towards patients’ clinical disease activity: stage A, active disease, focused on medical and surgical treatment optimisation; stage B, optimised treatments with a seton in situ, focused on definitive surgical management; and stage C, healed disease, focused on treatment maintenance. Endpoints included: [1] clinical fistula healing after a minimum of 12 months follow-up; [2] changes in radiologic disease activity and fibrosis on serial magnetic resonance imaging; and [3] proportion of patients requiring treatment optimisation. Results Sixty patients were included. At baseline, 47% were in stage A, 5% stage B, and 48% stage C. Median age was 40 years (IQR: 32-49), 52% were male, median perianal disease duration was 9 years (IQR: 2-16), and median attendance through the preexisting service was 6 years (IQR: 3-9). After a median of 22 months follow-up (IQR: 16-25), 83% had clinical healing which was significantly higher than baseline rates at study inclusion (83 vs 48%, p<0.001). For patients in stage A at baseline, 68% achieved clinical healing with estimated clinical healing rates of 39% (95%CI: 24-60) and 85% (95%CI: 64-97) at 1 and 2 years, respectively. This paralleled a significant reduction in radiologic disease activity and increase in radiologic fibrosis, with radiologic remission observed in 51% and radiologic response in 47% overall (Table 1). Patients who achieved clinical healing had significantly less radiologic disease activity and greater fibrosis compared to patients with non-healing fistulas. Overall, 53% had biologic dose escalation and 10% switched to an alternative biologic agent with the new care model. Thirty-seven percent underwent a median of two perianal surgical interventions (IQR: 1-3), 15% had closure or ablative techniques performed, and 15% had seton removal only. Conclusion A novel coordinated multi-disciplinary care model optimising medical and surgical treatments resulted in high rates of clinical healing and improved radiologic disease activity and fibrosis of Crohn’s perianal fistulas. Controlled-matched studies evaluating treatment optimisation are needed.

gastroenterology & hepatology
[Control of bone remodeling by nervous system. Possible roles of pituitary hormones for bone metabolism].

Y. Takeuchi

2010-12-01

Abstract:Accumulating evidence clearly indicates both thyroid hormone and estrogen have a pivotal role in bone metabolism. Pituitary hormones, TSH and FSH, regulate circulating levels of thyroid hormone and estrogen, respectively. Recent works raise a possibility that either TSH or FSH also has its own direct effects on bone cells involved in bone resorption and formation. More recently, it is suggested that oxytocin and vasopressin are also involved in bone metabolism. However, several investigations of genetically manipulated model mice and clinical data from patients with certain diseases have provided inconsistent results. Thus, we need more data that answer the question whether or not each pituitary hormone is physiologically and pathophysiologically involved in controlling bone metabolism in human.
Multi-national observational study to assess quality of life and treatment preferences in patients with Crohn's perianal fistulas

Chitra Karki,Amod Athavale,Vijay Abilash,Gary Hantsbarger,Parnia Geransar,Kate Lee,Slobodan Milicevic,Marko Perovic,Leanne Raven,Magdalena Sajak-Szczerba,Abigail Silber,Annabelle Yoon,Phil Tozer

DOI: https://doi.org/10.4240/wjgs.v15.i11.2537

2023-11-27

World J Gastrointest Surg

Abstract:Background: Patients with Crohn's disease (CD) are at risk of developing complications such as perianal fistulas. Patients with Crohn's perianal fistulas (CPF) are affected by fecal incontinence (FI), bleeding, pain, swelling, and purulent perianal discharge, and generally face a higher treatment burden than patients with CD without CPF. Aim: To gain insights into the burden of illness/quality of life in patients with CPF and their treatment preferences and satisfaction. Methods: This cross-sectional observational study was conducted in patients with CD aged 21-90 years via a web-enabled questionnaire in seven countries (April-August 2021). Patients were recruited into three cohorts: Cohort 1 included patients without perianal fistulas; cohort 2 included patients with perianal fistulas without fistula-related surgery; and cohort 3 included patients with perianal fistulas and fistula-related surgery. Validated patient-reported outcome measures were used to assess quality of life. Drivers of treatment preferences were measured using a discrete choice experiment (DCE). Results: In total, 929 patients were recruited (cohort 1, n = 620; cohort 2, n = 174; cohort 3, n = 135). Short Inflammatory Bowel Disease Questionnaire scores were worse for patients with CPF (cohorts 2 and 3) than for those with CD without CPF (cohort 1): Mean score 3.8 and 3.7 vs 4.1, respectively, (P < 0.001). Similarly, mean Revised FI and FI Quality of Life scores were worse for patients with CPF than for those with CD without CPF. Quality of Life with Anal Fistula scores were similar in patients with CPF with or without CPF-related surgery (cohorts 2 and 3): Mean score 41 and 42, respectively. In the DCE, postoperative discomfort and fistula healing rate were the most important treatment attributes influencing treatment choice: Mean relative importance 35.7 and 24.7, respectively. Conclusion: The burden of illness in CD is significantly higher for patients with CPF and patients rate lower postoperative discomfort and higher healing rates as the most desirable treatment attributes.
Perianal Fistulizing Crohn's Disease: Outcomes of Surgical Repairs and Current State of Stem Cell-Based Therapies

Aaron J. Dawes,Amy L. Lightner

DOI: https://doi.org/10.1055/s-0044-1786543

2024-05-17

Clinics in Colon and Rectal Surgery

Abstract:Perianal fistulizing Crohn's disease is one of the most disabling phenotypes of Crohn's disease, due to the severe impairment in quality of life including social and personal wellbeing. A multimodal approach with patient-tailored care is the key to optimal management of this condition. Medical therapy is needed to optimize the luminal disease, and surgical intervention is required to control any associated perianal sepsis and attempt palliative or definitive fistula repair. While several medical and surgical options are available, the majority of patients continue to have symptomatic disease. Fortunately, this continues to drive novel innovations which are revolutionizing the treatment and outcomes of perianal fistulizing Crohn's disease. However, there continues to be a need for randomized trials and consistent metrics utilized for classification and treatment outcomes in order to accurately describe optimal treatment outcomes. Article published online: 15 May 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

gastroenterology & hepatology,surgery
Management of Perianal Crohn's Disease

Alyssa M Parian,Megan Obi,Phillip Fleshner,David A Schwartz

DOI: https://doi.org/10.14309/ajg.0000000000002326

2023-08-01

Abstract:Perianal Crohn's disease affects 25%-35% of patients with Crohn's disease and has proven to be one of the most difficult complications of the disease to treat. Patients with perianal Crohn's disease have lower health-related quality of life scores typically related to pain and fecal incontinence. In addition, patients with perianal Crohn's disease have higher rates of hospitalizations, surgeries, and overall healthcare costs. A multidisciplinary approach is necessary for the successful management of Crohn's disease with perianal fistula. Medical management is required to treat the underlying immune dysregulation to heal the luminal inflammation and the inflammation within the fistula tracts. Current options for medical therapy include biologics, dual therapy with thiopurines, therapeutic drug monitoring, and a close follow-up. Surgical management is critical to drain abscesses before immunosuppressive therapy and place setons when appropriate. Once the patient's inflammatory burden is well managed, definitive surgical therapies including fistulotomies, advancement flaps, and ligation of intersphincteric fistula tract procedures can be considered. Most recently, the use of stem cell therapy in the treatment of perianal fistula has given new hope to the cure of perianal fistula in Crohn's disease. This review will outline the most current data in the medical and surgical management of perianal Crohn's disease.
OP31 Single-cell analyses identify immune and stromal signatures of perianal fistulizing Crohn's Disease

S Cao,K Nguyen,M Colonna,P Deepak

DOI: https://doi.org/10.1093/ecco-jcc/jjad212.0031

2024-01-01

Journal of Crohn's and Colitis

Abstract:Abstract Background Perianal fistulas occur in ~30-40% of Crohn’s disease (CD) patients associated with high morbidity and an impaired quality of life. The management of perianal fistulizing CD is a major clinical challenge, where its underlying etiology remains poorly understood. Methods We recruited patients with 1) CD with perianal fistulas (PCD; n = 12); 2) CD without perianal involvement (NPCD; n = 10); 3) idiopathic perianal fistulas (IPF; n = 21). Biopsies were taken from the fistula tracts, external opening of the fistulas, and rectal mucosa during examination under anesthesia or colonoscopy. Mucosal immune cells were analyzed using mass cytometry (or CyTOF), while all cells from PCD and IPF fistula tracts (n = 5 or 6) were characterized using single-cell RNA-sequencing. Results CyTOF revealed a skewed mucosal immune landscape in PCD. E.g., PCD fistula tracts harbored elevated CD45RO+ T cells including Tregs with increased expression of TIGIT and CD226 compared to IPF. PCD also expanded Th17 cells in the fistula tracts and IL-17-producing CD8 T cells (Tc17) in the rectum. Altered exhaustion markers CD39 and CD127 were present in both CD4 and CD8 T cells from PCD fistula tracts, external fistula openings, and rectum compared to IPF and NPCD. Regulatory B cells (Bregs), with immunomodulatory function in the gut, were dramatically diminished in PCD compared to IPF. In addition, PCD fistula tracts, fistula opening, and rectum all exhibited substantially higher CD172+TREM1+ macrophages, which were previously found to promote luminal CD (Figure 1; only fistula tract data are shown). Using scRNA-seq, we unraveled immune and stromal cell compartments in PCD and IPF fistula tracts (Figure 2). We also identified a small mast cell population, which was diminished in PCD. Mast cells are involved in tissue repair and remodeling in other diseases, although their presence in perianal fistulas was previously unknown. Three fibroblast populations (cluster 4, 6, 7 in figure 2D), with elevated activities in interferon signaling, IL-6-JAK-STAT3 pathway, TNF signaling, as well as TGF-B and epithelial-mesenchymal transition, were dramatically increased in PCD compared to IPF. Ongoing studies are focusing on spatial transcriptomics and functional analysis of fistula-associated immune cells and fibroblasts. Conclusion Using single cell analysis of the fistula tracts and nearby tissues from an extensive patient population, we revealed previously unknown immune and stromal cell landscapes of PCD. Our findings highlight the pathogenic roles of IL-17 signaling, T cell exhaustion, pathogenic macrophages, and pro-inflammatory/remodeling fibroblasts in the pathogenesis of PCD. This study may open new avenues for disease-specific therapies for this challenging condition.

gastroenterology & hepatology
Consensus definition of a radiologically healed fistula on magnetic resonance imaging in perianal Crohns disease: an international Delphi study

Easan Anand,Jalpa Devi,Shivani Joshi,Anna Antoniou,Michelle Doering,Jaap Stoker,Phillip Lung,Ailsa L Hart,David H Ballard,Parakkal Deepak,Phil Tozer

DOI: https://doi.org/10.1136/bmjopen-2024-087919

IF: 3.006

2024-11-26

BMJ Open

Abstract:Introduction Perianal fistulising Crohn's disease (pfCD) is a distinct and debilitating phenotype seen in around one-third of patients with CD. Clinical trials in pfCD are increasingly using magnetic resonance imaging (MRI) criteria as a primary endpoint, but there is heterogeneity in the radiological definition of a healed perianal fistula that currently limits our ability to perform meaningful meta-analyses of studies. Our aim is to standardise outcomes through the generation of an international consensus definition of a radiologically healed fistula. Methods and analysis This international Delphi consensus study employs a two-part strategy. The first is a systematic review to identify a longlist of variables used to define radiological healing in pfCD. MRI-based indices used to score fistula severity and healing will be assessed for their methodological quality using Consensus-based Standards for the selection of health Measurement Instruments (COSMIN). The systematic review protocol will be conducted using COSMIN methodology and reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The second part will be an online Delphi consensus, guided by the results of the systematic review. Radiologists, gastroenterologists and colorectal surgeons with expertise in the management of pfCD will be invited to take part in two to three rounds of online surveys. Once an a priori threshold of >80% agreement is reached on individual radiological components used to define 'healing' and 'healed', a final meeting of key stakeholders will be organised to generate a consensus definition of a healed fistula. Ethics and dissemination The study has been deemed exempt from a formal Research Ethics Committee review as no patients will participate directly in the consensus process, given the technical nature of the research question. The study is registered with the local R&D department (Reference RD24/007). Publication of this study will help standardise radiological endpoint measurement in clinical trials of pfCD and improve the synthesis and meta-analysis of comparative studies. PROSPERO registration number CRD42024504334.

medicine, general & internal
Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review

Julian Panes,Walter Reinisch,Ewa Rupniewska,Shahnaz Khan,Joan Forns,Javaria Mona Khalid,Daniela Bojic,Haridarshan Patel

DOI: https://doi.org/10.3748/wjg.v24.i42.4821

2018-11-14

Abstract:Aim: To systematically review the literature on epidemiology, disease burden, and treatment outcomes for Crohn's disease (CD) patients with complex perianal fistulas. Methods: PubMed, Embase, and Cochrane were searched for relevant articles (published 2000-November 2016) and congress abstracts (published 2011-November 2016). Results: Of 535 records reviewed, 62 relevant sources were identified (mostly small observational studies). The cumulative incidence of complex perianal fistulas in CD from two referral-centre studies was 12%-14% (follow-up time, 12 years in one study; not reported in the second study). Complex perianal fistulas result in greatly diminished quality of life; up to 59% of patients are at risk of faecal incontinence. Treatments include combinations of medical and surgical interventions and expanded allogeneic adipose-derived stem cells. High proportions of patients experience lack of or inadequate response to treatment (failure and relapse rates, respectively: medical, 12%-73% and 0%-41%; surgical: 0%-100% and 11%-20%; combined medical/surgical: 0%-80% and 0%-50%; stem cells: 29%-47% and not reported). Few studies (1 of infliximab; 3 of surgical interventions) have been conducted in treatment-refractory patients, a population with high unmet needs. Limited data exist on the clinical value of anti-tumour necrosis factor-α dose escalation in patients with complex perianal fistulas in CD. Conclusion: Complex perianal fistulas in CD pose substantial clinical and humanistic burden. There is a need for effective treatments, especially for patients refractory to anti-tumour necrosis factor-α agents, as evidenced by high failure and relapse rates.
Single-Cell and Spatial Multi-omics Reveal Interferon Signaling in the Pathogenesis of Perianal Fistulizing Crohn's Disease

Siyan Cao,Khai M Nguyen,Kaiming Ma,Xin Yao,Ta-Chiang Liu,Malek Ayoub,Jalpa Devi,Yizhou Liu,Radhika Smith,Matthew Silviera,Steven R Hunt,Paul E Wise,Matthew G Mutch,Sean C Glasgow,William C Chapman Jr.,Michelle Cowan,Mathew A Ciorba,Marco Colonna,Parakkal Deepak

DOI: https://doi.org/10.1101/2024.11.08.620717

2024-11-10

Abstract:Background & Aims: Perianal fistulizing Crohn's disease (PCD) is a common and debilitating complication with elusive pathophysiology. We examined mucosal cells from patients with PCD and related conditions using a multi-omics approach. Methods: We recruited patients with PCD (n = 24), CD without perianal disease (NPCD, n = 10), and idiopathic perianal fistulas (IPF, n = 29). Biopsies were taken from fistula tracts, fistula opening, and rectal mucosa. Single-cell RNA-sequencing (scRNA-seq), mass cytometry (CyTOF), spatial transcriptomics (ST), immunohistochemistry, and integrated analysis were performed. Results: ScRNA-seq, CyTOF, and ST unraveled immune and non-immune cell compartments in PCD and IPF fistula tracts. PCD fistulas showed hyperactivated pathogenic pathways including interferon (IFN)G response and TNF signaling in myeloid and stromal cells. Intestinal cells from PCD patients also expressed greater levels of IFNG-responsive and EMT genes compared to NPCD patients. Furthermore, both fistula tracts and ileal mucosa from PCD patients harbored expanded IFNG+ pathogenic Th17 cells, which expressed elevated inflammatory mediators. CyTOF also identified skewed immune cell phenotypes in the fistula tracts, fistula opening, and rectum in PCD patients including expanded Th17 cells, increased pathogenic myeloid cells, and altered T cell exhaustion markers. Further analysis also revealed cellular modules associated with anti-TNF therapy in PCD patients. Conclusion: Multi-omics analysis revealed immune, stromal, and epithelial cell landscapes of PCD, which highlight the pathogenic role of hyperactivated IFNG signaling in both fistula tracts and luminal mucosa. This study identified IFNG as a potential therapeutic target for PCD.

Systems Biology

Letter: Tonsillectomy bleeding.

P934 A delphi consensus on the optimisation of medical and surgical therapy in perianal fistulising Crohn’s disease, targeted at individual TOpCLASS classification groups

TOpCLASS Expert Consensus Classification of Perianal Fistulizing Crohn’s Disease: A Real-World Application in a Serial Fistula MRI Cohort

Perianal Fistulizing Crohn's Disease-Associated Anorectal and Fistula Cancers: Systematic Review and Expert Consensus

DOP04 Screening and management of fistula cancers in patients with perianal fistulising Crohn’s Disease: an expert consensus

P498 An expert Delphi consensus: Early identification of patients at risk of Crohn's disease in perianal fistulas and abscesses (PREFAB) and identification and management of isolated perianal Crohn's disease (ipCD) - Part B, ipCD

Soft tissue inflammations-bursitis-tendinitis-synovitis.

Perianal fistulizing Crohn's disease: Current perspectives on diagnosis, monitoring and management with a focus on emerging therapies

P946 Real life management of patients with active perianal fistulizing Crohn’s disease (ALERT-CD study)

P736 Class 4 Fistulizing Perineal Disease after Proctectomy for Crohn’s Disease: A Multicentre Study

P199 Analysis of Clinical Features of Asymptomatic Perianal Fistulizing Crohn’s Disease

P1129 Fistulising Crohn's Disease in a large Australasian cohort - Crohn's Colitis Cure (CCC) Data Insights Program

P547 Improved clinical and radiologic healing of Crohn’s perianal fistulas using a novel coordinated care model optimising medical and surgical treatments: A prospective real-world observational study

[Control of bone remodeling by nervous system. Possible roles of pituitary hormones for bone metabolism].

Multi-national observational study to assess quality of life and treatment preferences in patients with Crohn's perianal fistulas

Perianal Fistulizing Crohn's Disease: Outcomes of Surgical Repairs and Current State of Stem Cell-Based Therapies

Management of Perianal Crohn's Disease

OP31 Single-cell analyses identify immune and stromal signatures of perianal fistulizing Crohn's Disease

Consensus definition of a radiologically healed fistula on magnetic resonance imaging in perianal Crohns disease: an international Delphi study

Burden and outcomes for complex perianal fistulas in Crohn's disease: Systematic review

Single-Cell and Spatial Multi-omics Reveal Interferon Signaling in the Pathogenesis of Perianal Fistulizing Crohn's Disease